We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience.
- Authors
Arnott, I. D. R.; McDonald, D.; Williams, A.; Ghosh, S.
- Abstract
Introduction:Infliximab is an established treatment for steroid-resistant and fistulating Crohn’s disease. Although efficacy has been shown in clinical trials, financial implications often limit its use and limited data exist regarding clinical practice. Aims:To audit the clinical effectiveness of Infliximab. Methods:We prospectively audited 50 consecutive patients [28 females; median age, 34 years (17–70 years)]. Disease activity and response rates were assessed by the Harvey–Bradshaw index. Clinical and disease data were collected and blood was taken for inflammatory markers, complement and double-stranded DNA antibodies. Patients received Infliximab at 5 mg/kg and were followed for 12 weeks. Results:Indications for Infliximab were refractory Crohn’s disease in 39 patients, fistulating Crohn’s disease in six, pyoderma gangrenosum in one, pouchitis in two and coeliac disease in two. Thirty-one (79%) of the refractory Crohn’s disease patients and four (66%) of the fistulating patients responded at 4 weeks. Twenty-one (54%) of the refractory Crohn’s disease patients had a continued response at 12 weeks. Perianal disease was more prevalent in non-responders (7/8 vs. 12/31, P < 0.02). Conclusions:Response rates to Infliximab in our group are comparable to those of clinical trials. Despite the expense, it remains a useful adjunct to treatment in this otherwise difficult group of patients. Patients with perianal disease responded less well in our cohort.
- Subjects
INFLAMMATORY bowel disease treatment; ANUS; PRECANCEROUS conditions
- Publication
Alimentary Pharmacology & Therapeutics, 2001, Vol 15, Issue 10, p1639
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1046/j.1365-2036.2001.01092.x